These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

69 related items for PubMed ID: 18617908

  • 1. Persistency with medical treatment for glaucoma and ocular hypertension in the United Kingdom: 1994-2005.
    Owen CG, Carey IM, de Wilde S, Whincup PH, Wormald R, Cook DG.
    Eye (Lond); 2009 May; 23(5):1098-110. PubMed ID: 18617908
    [Abstract] [Full Text] [Related]

  • 2. The epidemiology of medical treatment for glaucoma and ocular hypertension in the United Kingdom: 1994 to 2003.
    Owen CG, Carey IM, De Wilde S, Whincup PH, Wormald R, Cook DG.
    Br J Ophthalmol; 2006 Jul; 90(7):861-8. PubMed ID: 16782949
    [Abstract] [Full Text] [Related]

  • 3. [Early adherence to anti-glaucoma therapy: An observational study].
    Belhassen M, Laforest L, Licaj I, Van Ganse É.
    Therapie; 2016 Oct; 71(5):491-499. PubMed ID: 27203158
    [Abstract] [Full Text] [Related]

  • 4. Costs and persistence of carbonic anhydrase inhibitor versus alpha-2 agonists, associated with beta-blockers, in glaucoma and ocular hypertension: an analysis of the UK-GPRD database.
    Lafuma A, Berdeaux G.
    Curr Med Res Opin; 2008 May; 24(5):1519-27. PubMed ID: 18413015
    [Abstract] [Full Text] [Related]

  • 5. Persistency rates for prostaglandin and other hypotensive eyedrops: population-based study using pharmacy claims data.
    Rait JL, Adena MA.
    Clin Exp Ophthalmol; 2007 May; 35(7):602-11. PubMed ID: 17894679
    [Abstract] [Full Text] [Related]

  • 6. Persistence and adherence with topical glaucoma therapy.
    Nordstrom BL, Friedman DS, Mozaffari E, Quigley HA, Walker AM.
    Am J Ophthalmol; 2005 Oct; 140(4):598-606. PubMed ID: 16226511
    [Abstract] [Full Text] [Related]

  • 7. Changing Initial Glaucoma Medical Therapy Increases Healthcare Resource Utilization.
    Trese MGJ, Lewis AW, Blachley TS, Stein JD, Moroi SE.
    J Ocul Pharmacol Ther; 2017 Oct; 33(8):591-597. PubMed ID: 28854348
    [Abstract] [Full Text] [Related]

  • 8. Combination therapy as initial treatment in glaucoma and suspected glaucoma.
    Mikelberg FS, Etminan M.
    Can J Ophthalmol; 2012 Jun; 47(3):240-2. PubMed ID: 22687299
    [Abstract] [Full Text] [Related]

  • 9. A randomized, 36-month, post-marketing efficacy and tolerability study in Sweden and Finland of latanoprost versus non-prostaglandin therapy in patients with glaucoma or ocular hypertension.
    Friström B, Uusitalo H.
    Acta Ophthalmol; 2010 Feb; 88(1):37-43. PubMed ID: 19900212
    [Abstract] [Full Text] [Related]

  • 10. Intraocular pressure control and persistence on treatment in glaucoma and ocular hypertension.
    Tingey D, Bernard LM, Grima DT, Miller B, Lam A.
    Can J Ophthalmol; 2005 Apr; 40(2):161-9. PubMed ID: 16049529
    [Abstract] [Full Text] [Related]

  • 11. Association of ocular hypotensive medication types with dynamic contour tonometry and Goldmann applanation tonometry measurements in a glaucoma and ocular hypertensive population.
    Tzamalis A, Kynigopoulos M, Chalvatzis N, Dimitrakos S, Schlote T.
    J Ocul Pharmacol Ther; 2013 Feb; 29(1):41-7. PubMed ID: 23066787
    [Abstract] [Full Text] [Related]

  • 12. A persistency and economic analysis of latanoprost, bimatoprost, or beta-blockers in patients with open-angle glaucoma or ocular hypertension.
    Day DG, Schacknow PN, Sharpe ED, Ellyn JC, Kulze JC, Threlkeld AB, Jones ED, Brown RH, Jenkins JN, Stewart WC.
    J Ocul Pharmacol Ther; 2004 Oct; 20(5):383-92. PubMed ID: 15650513
    [Abstract] [Full Text] [Related]

  • 13. Switch to latanoprost monotherapy from combined treatment with beta-antagonist and other antiglaucoma agents in patients with glaucoma or ocular hypertension.
    Ito K, Goto R, Matsunaga K, Sugimoto K, Uji Y.
    Jpn J Ophthalmol; 2004 Oct; 48(3):276-80. PubMed ID: 15175922
    [Abstract] [Full Text] [Related]

  • 14. Medication adherence and health care costs with the introduction of latanoprost therapy for glaucoma in a Medicare managed care population.
    Bhosle MJ, Reardon G, Camacho FT, Anderson RT, Balkrishnan R.
    Am J Geriatr Pharmacother; 2007 Jun; 5(2):100-11. PubMed ID: 17719512
    [Abstract] [Full Text] [Related]

  • 15. [Beta-blockers or prostaglandins: which is the better choice?].
    Denis P.
    J Fr Ophtalmol; 2009 Mar; 32(3):206-11. PubMed ID: 19515335
    [Abstract] [Full Text] [Related]

  • 16. Glaucoma treatment adherence at a United Kingdom general practice.
    Tse AP, Shah M, Jamal N, Shaikh A.
    Eye (Lond); 2016 Aug; 30(8):1118-22. PubMed ID: 27256302
    [Abstract] [Full Text] [Related]

  • 17. Accounting for restart rates in evaluating persistence with ocular hypotensives.
    Schwartz GF, Platt R, Reardon G, Mychaskiw MA.
    Ophthalmology; 2007 Apr; 114(4):648-52. PubMed ID: 17398318
    [Abstract] [Full Text] [Related]

  • 18. Persistency and treatment failure in newly diagnosed open angle glaucoma patients in the United Kingdom.
    Zhou Z, Althin R, Sforzolini BS, Dhawan R.
    Br J Ophthalmol; 2004 Nov; 88(11):1391-4. PubMed ID: 15489479
    [Abstract] [Full Text] [Related]

  • 19. Intraocular pressure response to medication in a clinical setting: the Marshfield Clinic Personalized Medicine Research Project.
    McCarty CA, Mukesh BN, Kitchner TE, Hubbard WC, Wilke RA, Burmester JK, Patchett RB.
    J Glaucoma; 2008 Aug; 17(5):372-7. PubMed ID: 18703947
    [Abstract] [Full Text] [Related]

  • 20. Physicians' treatment decisions, patient persistence, and interruptions in the continuous use of prostaglandin therapy in glaucoma.
    Hahn SR, Kotak S, Tan J, Kim E.
    Curr Med Res Opin; 2010 Apr; 26(4):957-63. PubMed ID: 20163296
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.